About Antiva biosciences
Antiva Biosciences: Developing Novel Topical Therapies to Treat Pre-Cancerous Lesions Caused by HPV
Antiva Biosciences is a biopharmaceutical company that is dedicated to developing novel topical therapies for the treatment of pre-cancerous lesions caused by human papillomavirus (HPV). The company's mission is to provide effective and safe treatments for patients who are at risk of developing cervical cancer, which is one of the most common types of cancer in women worldwide.
Antiva Biosciences was founded in 2015 by Dr. Gail Naughton, a renowned scientist and entrepreneur who has over 30 years of experience in the field of regenerative medicine. Dr. Naughton's vision was to create a company that would focus on developing innovative therapies for unmet medical needs, particularly those related to women's health.
The company's lead product candidate, ABI-1968, is a topical therapy that targets pre-cancerous lesions caused by HPV. This therapy works by inhibiting the activity of E6 and E7 proteins produced by high-risk strains of HPV. These proteins are known to play a critical role in the development and progression of cervical cancer.
ABI-1968 has shown promising results in preclinical studies, demonstrating potent antiviral activity against multiple strains of HPV as well as excellent safety profiles. The therapy has also been shown to induce regression or complete clearance of pre-cancerous lesions in animal models.
Antiva Biosciences' approach differs from traditional treatments for cervical dysplasia, which often involve invasive procedures such as surgery or cryotherapy. ABI-1968 offers an alternative option that could potentially reduce the need for these procedures while providing effective treatment with minimal side effects.
In addition to its lead product candidate, Antiva Biosciences has several other programs focused on developing novel therapies for women's health issues such as bacterial vaginosis and vulvodynia. The company's pipeline includes both small molecule and biologic therapies that target specific molecular pathways involved in these conditions.
Antiva Biosciences has received funding from several sources, including venture capital firms, government grants, and partnerships with pharmaceutical companies. The company has also established collaborations with leading academic institutions to advance its research programs.
The team at Antiva Biosciences is comprised of experienced scientists and executives who are dedicated to advancing the company's mission. The company's leadership team includes Dr. Gail Naughton as CEO, Dr. Karl Hostetler as Chief Medical Officer, and Dr. David Boyle as Chief Scientific Officer.
In conclusion, Antiva Biosciences is a biopharmaceutical company that is developing novel topical therapies for the treatment of pre-cancerous lesions caused by HPV. Its lead product candidate ABI-1968 has shown promising results in preclinical studies and offers an alternative option to traditional treatments for cervical dysplasia. With a strong pipeline of programs focused on women's health issues, Antiva Biosciences is poised to make a significant impact in the field of regenerative medicine.